Shares of Juno Therapeutics Inc (NASDAQ:JUNO) have been given an average rating of “Hold” by the twenty research firms that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $51.94.

A number of analysts recently weighed in on JUNO shares. Raymond James Financial upped their price objective on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. Zacks Investment Research lowered Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Citigroup restated a “buy” rating and issued a $59.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Wells Fargo & Co lowered Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 12th. Finally, Wedbush restated an “outperform” rating and issued a $64.00 price objective (up previously from $42.00) on shares of Juno Therapeutics in a report on Thursday, November 2nd.

In other Juno Therapeutics news, CFO Steve Harr sold 8,750 shares of the stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $391,650.00. Following the transaction, the chief financial officer now owns 772,082 shares of the company’s stock, valued at approximately $34,558,390.32. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Robert Azelby sold 6,666 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total value of $366,296.70. Following the completion of the sale, the executive vice president now directly owns 79,998 shares in the company, valued at approximately $4,395,890.10. The disclosure for this sale can be found here. Insiders have sold 65,956 shares of company stock worth $3,064,378 over the last quarter. 15.08% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its holdings in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 228 shares during the last quarter. Pacad Investment Ltd. acquired a new stake in Juno Therapeutics during the second quarter valued at $105,000. Advisor Group Inc. boosted its position in Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,439 shares during the last quarter. QS Investors LLC acquired a new stake in Juno Therapeutics during the second quarter valued at $135,000. Finally, Bronfman E.L. Rothschild L.P. raised its holdings in Juno Therapeutics by 27,376.9% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 3,559 shares in the last quarter. Institutional investors own 69.94% of the company’s stock.

Shares of Juno Therapeutics (JUNO) traded up $1.15 during mid-day trading on Monday, hitting $50.09. 2,100,000 shares of the stock were exchanged, compared to its average volume of 2,350,000. Juno Therapeutics has a 52-week low of $18.90 and a 52-week high of $63.45. The company has a market capitalization of $5,720.00, a price-to-earnings ratio of -14.78 and a beta of 2.32. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter in the previous year, the business posted ($0.57) earnings per share. The business’s revenue was up 115.4% compared to the same quarter last year. sell-side analysts forecast that Juno Therapeutics will post -4.02 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/analysts-set-juno-therapeutics-inc-juno-price-target-at-49-85/1803589.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.